Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/32927
Title: | Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure | Authors: | Seferovic, Petar M. Fragasso, Gabriele Petrie, Mark MULLENS, Wilfried Ferrari, Roberto Thum, Thomas Bauersachs, Johann Anker, Stefan D. Ray, Robin Cavusoglu, Yuksel Polovina, Marija Metra, Marco Ambrosio, Giuseppe Prasad, Krishna Seferovic, Jelena Jhund, Pardeep S. Dattilo, Giuseppe Celutkiene, Jelena Piepoli, Massimo Moura, Brenda Chioncel, Ovidiu Ben Gal, Tuvia Heymans, Stephane Jaarsma, Tiny Hill, Loreena Lopatin, Yuri Lyon, Alexander R. Ponikowski, Piotr Lainscak, Mitja Jankowska, Ewa Mueller, Christian Cosentino, Francesco Lund, Lars H. Filippatos, Gerasimos S. Ruschitzka, Frank Coats, Andrew J. S. Rosano, Giuseppe M. C. |
Issue Date: | 2020 | Publisher: | WILEY | Source: | EUROPEAN JOURNAL OF HEART FAILURE, 22 (11) , p. 1984 -1986 | Abstract: | The Heart Failure Association (HFA) of the European Society of Cardiology (ESC) has recently issued a position paper on the role of sodium-glucose co-transporter 2 (SGLT2) inhibitors in heart failure (HF). The present document provides an update of the position paper, based of new clinical trial evidence. Accordingly, the following recommendations are given: center dot Canagliflozin, dapagliflozin empagliflozin, or ertugliflozin have consistently demonstrated to be effective for the prevention of HF hospitalization in patients with type 2 diabetes mellitus and established cardiovascular disease or at high cardiovascular risk. The specifically listed agents are recommended. center dot Dapagliflozin or empagliflozin are recommended to reduce the combined risk of HF hospitalization and cardiovascular death in symptomatic patients with HF and reduced ejection fraction, already receiving guideline-directed medical therapy, regardless of the presence of type 2 diabetes mellitus. | Notes: | Seferovic, PM (corresponding author), Univ Belgrade, Fac Med, Heart Failure Soc Serbia, 8 Koste Todorovica, Belgrade 11000, Serbia. seferovic.petar@gmail.com |
Other: | Seferovic, PM (corresponding author), Univ Belgrade, Fac Med, Heart Failure Soc Serbia, 8 Koste Todorovica, Belgrade 11000, Serbia. seferovic.petar@gmail.com | Keywords: | Heart failure;Sodium–glucose co‐transporter 2 inhibitors;Type 2 diabetes mellitus;Cardiovascular outcomes;Renal function | Document URI: | http://hdl.handle.net/1942/32927 | ISSN: | 1388-9842 | e-ISSN: | 1879-0844 | DOI: | 10.1002/ejhf.2026 | ISI #: | WOS:000585897600001 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2021 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ejhf.2026.pdf | Published version | 488.86 kB | Adobe PDF | View/Open |
WEB OF SCIENCETM
Citations
66
checked on Oct 14, 2024
Page view(s)
22
checked on Jun 21, 2022
Download(s)
4
checked on Jun 21, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.